Diabetes Surveillance System has estimated that 6.2% of the population have diabetes [1] . In Alberta, 206,000 people were living with diabetes in 2009, representing over 5.5% of the population [2] . This signifies a doubling of affected individuals within the past decade. The majority (i.e., >90%) of these individuals have type 2 diabetes. As the number of people with diabetes increases, the number of resulting complications and co-morbidities increases, creating a greater demand on health care resources [2] [3] . The Alberta's Caring for Diabetes (ABCD) Project, funded by the Alberta Health ministry as part of the provincial diabetes strategy, was developed to improve the quality and efficiency of care for diabetes in Alberta, Canada, with a focus on supporting Primary Care Networks (PCNs) in non-metro areas of Alberta. PCNs consist of a voluntary network of family physicians (hereby referred to as "member physicians") and allied health professionals, who identify priorities and coordinate health services for patient populations [4] [5] . The PCN model is akin to the "patient-centered medical home" model emerging in the United States [6] [7] .
The ABCD team has worked with participating PCNs to implement a number of quality improvement interventions. This includes an ongoing, survey-based cohort study that seeks to understand why some people with type 2 diabetes develop complications while others do not. This study involves an annual survey of individuals with type 2 diabetes over five years, to collect data on lifestyle behaviours, self-management and patient-reported outcomes and linkage with administrative databases to assess health care utilization and longer term clinical outcomes. In addition, participating PCNs will implement pilot interventions including: (1) Healthy Eating and Active Living in Diabetes (HEALD-PCN), a pedometer-based walking program [8] ; and (2) TeamCare-PCN, a collaborative teambased, depression case management intervention [9] . Key features of HEALD-PCN include the provision F o r p e e r r e v i e w o n l y 5 of information in a group setting by an exercise specialist on increasing the amount and intensity of physical activity (i.e., walking), the glycemic index, and individual goal setting. The HEALD-PCN program also provides opportunities for participants to implement lessons learned (i.e., walking group sessions) through partnerships with community recreational facilities [10] . Key features of TeamCare-PCN include coordinated care by a nurse care manager (CM) to direct active patient follow-up, treat-to-target principles, and specialist (i.e., psychiatrists and internists/endocrinologists) consultation [11] .
The efficacy of both pilot interventions has been proven in other settings [10] [11] [12] , and the study protocols to determine the effectiveness of HEALD-PCN and TeamCare-PCN in the PCN environment in Alberta have been published [8] [9] . Our goal is to also assess the impact of the entire ABCD project activities, including how these different interventions were simultaneously implemented, in Alberta's PCN environment. The purpose of this paper is to describe the design of the evaluation for the different elements of the ABCD project, using the RE-AIM framework [13] .
Evaluating the ABCD pilot interventions using RE-AIM
The gaps between health research, policy and practice have been well documented [13] [14] [15] [16] .
Evaluations of health interventions are often limited to efficacy studies rather than assessment of potential public health impact [17] . Efficacy studies tend to focus on the internal validity of highintensity health interventions with motivated and homogenous populations in controlled settings [13] .
This narrow focus hinders the translation of research into practice and reduces the ability to generalize findings to similar settings [13] . Evidence on the external validity of less-intensive interventions in realworld settings is needed to better inform decisions about practice [13] .
In this context, assessment of clinical effectiveness alone is not enough to inform decisions about a program's broader public health impact. The RE-AIM evaluation framework was designed to assess health interventions beyond effectiveness to include multiple criteria to better identify effect and Effectiveness of the intervention; Adoption by target settings, institutions and staff; Implementation, including consistency and cost of delivery; and Maintenance of intervention effects over time [13] .
The RE-AIM model addresses two levels of assessment: individual (Reach, Effectiveness); organization (Adoption and Implementation); or both (Maintenance) [13] . To fit our evaluation goals, we expanded the assessment level of "reach" [13] beyond the individual assessment level (i.e., absolute number, proportion, and representativeness of individuals willing to participate in an intervention) to include an organization assessment level (i.e., an organization's ability to identify the entire target population) ( Table 1 ). An example of an organizational strategy to identify a population is the development and use of a patient registry.
Table 1: RE-AIM dimensions, definitions, and assessment levels for evaluation of the ABCD pilot interventions Dimension Definition Level of Assessment Reach
The ability to identify targeted population(s) at an organizational level and the absolute number, proportion, and representativeness of individuals who are willing to participate in an intervention.
Individual & Organizational

Effectiveness
The impact of an intervention on important outcomes, including potential negative effects and quality of life.
Individual
Adoption
The absolute number, proportion, and representativeness of settings and intervention agents (i.e., people who deliver the program) who are willing to initiate an intervention Organizational Implementation At the individual level, implementation refers to clients' use of the intervention strategies. At the setting level, implementation refers to the intervention agents' fidelity to the various elements of an intervention's protocol, including consistency of delivery as intended, and the time and cost of the intervention.
Individual & Organizational
Maintenance
At the individual level, maintenance has been defined as the long-term effects of a program on outcomes 6 or more months after the most recent intervention contact. At the setting level, maintenance refers to the extent to which a program or policy becomes institutionalized or part of the routine organizational practices and policies.
Individual & Organizational
Italicized words or phrases indicate modifications made by the ABCD Project team to the original "Reach" definition and assessment level [13] . This 
METHODS AND ANALYSIS
We will employ a mixed-methods approach [22] for our comprehensive evaluation of the ABCD pilot interventions. Using the RE-AIM model, our research team developed logic models and data matrices for both interventions in consultation with advisory committees (Appendix 1; Web only file).
The overarching questions guiding the evaluation for each intervention are: (1) Is the service delivery model effective in the context of Alberta's primary care setting; and (2) What factors contribute to the effectiveness (or ineffectiveness) of the intervention? The more specific evaluation questions related to the RE-AIM framework that will direct the collection and analysis of data for both interventions include: 
Measurement by RE-AIM Dimensions
In the following section, we outline the measures proposed for each dimension of RE-AIM to evaluate the ABCD project interventions. A detailed summary is provided in Table 2 (Web file only).
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REACH
Evaluation of reach will be done at the individual (patient) and organization (PCN) assessment levels to determine if the ABCD pilot interventions are reaching those in most need. At the individual assessment level, we will examine total recruitment into the interventions and usual care groups and compare their characteristics with respect to eligibility criteria, demographic information, and other measures. As possible, we will compare characteristics between participants (i.e., intervention and usual care groups) and non-participants using aggregate demographic information accessed through PCN patient registries and Alberta Diabetes Surveillance System (ADSS) data [23] . Facilitators and barriers to individual patient recruitment and suggestions for improvement will be identified through interviews with PCN staff.
At the organization assessment level, we will document usual care in the PCNs, including the ability to estimate and identify target patient populations in the focus areas (i.e., type 2 diabetes management, depression management and lifestyle counseling) through completion of a standardized checklist. We will examine processes related to registry development and identify facilitators and barriers related to development, use, and maintenance through interviews with PCN staff. In addition, we will elicit recommendations related to the PCNs' ability to identify patient populations to actively offer targeted health services.
EFFECTIVENESS
Evaluation of effectiveness will be conducted at the individual assessment level to determine impact of the pilot interventions on important outcomes. The design and rationale for controlled evaluations of the effectiveness of the two ABCD pilot interventions have been described elsewhere [8] [9]. The primary outcome of HEALD-PCN is improvement in physical activity (i.e., brisk walking), 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   9 determined by step pedometers and self-report [8] . For TeamCare-PCN, the primary outcome is improvement of depressive symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9)
items [9] . We will also use a variety of measures to determine the effectiveness of both interventions on important outcomes at the individual assessment level including clinical measures (e.g., improvements
in glycemic control, blood pressure, lipid measurements, and body mass index), self-reported health- indicators. In addition, we will document unanticipated consequences (positive or negative), such as improved patient linkages with community health resources, to provide a richer understanding of effectiveness. Additional measures and data sources to assess effectiveness are provided in Table 2 .
ADOPTION
We will assess adoption of the ABCD pilot interventions at the organization level, including documentation of the criteria for PCN selection and participation in the ABCD Project and PCN Board approval. Also, we will document and compare the characteristics of the participating PCNs (e.g., number of family physicians, number of patients served, and governance structure) as well as usual care in the focus areas. Dependent on availability of secondary data, we will consider the representativeness of participating PCNs compared to non-participating PCNs. This will be accomplished through document review (e.g., ABCD project documents, PCN websites, business plans), use of a standardized usual care checklist, and interviews with PCN staff. In addition, perceptions related to the extent to which the ABCD pilot interventions have been adopted by the PCNs and modified to suit their contexts will be elicited through interviews with PCN staff. Identified facilitators and barriers to adoption of the interventions along with creative solutions or modifications will also be documented. 
IMPLEMENTATION
Evaluation of implementation of the ABCD pilot interventions will be done at the individual and organization assessment levels to determine patient adherence, consistency of implementation, and costs of delivering the pilot interventions. To address implementation at an individual assessment level, participant adherence to the intervention models will be determined for both interventions. For HEALD-PCN, attendance at group sessions, participant step logs (i.e., recording the number of steps over three days) and self-reported physical activity will be assessed. For TeamCare-PCN, adherence to treatment plans, including medication and behavioural modifications (e.g., engaging in planned pleasant activities), will be assessed. These types of data will be derived from patient outcome tracking systems employed in each PCN and/or survey items.
At the organization assessment level, consistency of implementation and the cost of delivering the ABCD pilot interventions will be evaluated to determine the practicality of the interventions. Actual versus intended implementation will be assessed through extensive documentation including development of project materials (e.g., training and resource materials), presence of systems and processes (e.g., patient registries), intervention staff recruited or hired by PCNs, and provision and quality of training in the intervention models. Additional measures and data sources to assess consistent implementation are provided in Table 2 . Our implementation assessment will also include economic evaluations of the ABCD pilot interventions, which have been described in detail elsewhere [8] [9] .
MAINTENANCE
For both ABCD pilot interventions, maintenance will be evaluated at the individual and organization assessment levels to measure continuation of intervention effects over time. We will use a previously developed conceptual framework that defines sustainability outcomes of health 
Data Management
Our comprehensive evaluation will involve the collection and management of a wide range and large volume of data. Primary data sources for the evaluation of the ABCD pilot interventions include:
(1) clinical outcome measures; (2) patient-reported outcomes; (3) interviews (e.g., with PCN staff, HEALD-PCN intervention group participants, and specialists for TeamCare-PCN); (4) document review (e.g., usual care checklists, project documents, field notes); and (5) administrative health care datasets.
Clinical outcomes and survey data captured in the patient outcome tracking systems or standardized case forms used in each PCN will be entered into centralized, web-accessible databases.
These study databases will be housed on secure servers in the research offices at the University of Alberta. Once the pilot interventions are completed, all data will be exported and merged, based on individually assigned study ID numbers, to form an analyzable dataset. Investigators, research assistants, and analysts will be masked to allocation status at all times.
Semi-structured interviews will take place at the PCN offices of the interviewees. Interviews with HEALD-PCN intervention group participants and TeamCare-PCN specialists will be conducted via telephone. Interviews will be facilitated through the use of interview guides. Interviews will be digitally recorded for subsequent analysis, transcribed verbatim by an independent transcriptionist, and verified for accuracy.
Regarding document review, we will develop a standardized usual care checklist by adapting qualitative data sources, including interview transcripts and documents, will be compiled and managed using Nvivo 9.0 software.
Patients enrolled in the pilot interventions and the ABCD Cohort study will be asked for permission to access their medical records by providing their personal health number, thus allowing linkage to provincial health care administrative data from Alberta Health for physician, hospital, and emergency department billing, and pharmaceutical data (for patients 65 years and older). This linkage will allow health care utilization and health care costs to be included in the evaluation.
Data Analysis
We are undertaking a broad mixed-methods approach to analysis. In terms of quantitative data, the approach to power, sample size calculations, assessment and statistical modeling of clinical effectiveness have been previously detailed [8] [9] . In terms of qualitative data, we will take a general inductive approach [33] with the evaluation questions related to the RE-AIM framework directing the analysis of data. Findings will be derived directly through a content analysis [34] of the raw data without preconceived notions about specific findings.
ETHICS AND DISSEMINATION Ethical Considerations
Ethics approval for the entire ABCD Project and its associated interventions has been granted from 
Discussion and Dissemination
The ABCD Project was developed to improve the quality and efficiency of diabetes care in nonmetro Alberta. In order to address the gap between research, policy, and practice, we have adapted and expanded the RE-AIM model to conduct a comprehensive evaluation of the ABCD pilot interventions.
This will contribute to our knowledge of the broader impact of the two interventions within the evolving primary care context of Alberta beyond effectiveness, as outlined in the study trial designs [8] [9] . The purpose of this article was to present the proposed measures and data sources to be used to evaluate the interventions by RE-AIM dimension. Using the RE-AIM evaluation framework will allow us to systematically identify facilitators, challenges, opportunities and lessons learned to be used in program planning and care delivery for patients with type-2 diabetes. In addition, our application of the RE-AIM evaluation framework may encourage others to use similar models to determine the impact of community-based primary health care interventions. The RE-AIM model will also be used to structure our dissemination activities. For example, each RE-AIM dimension will inform the development of products (such as academic manuscripts for peer-review publication, presentations at relevant conferences and workshops, and briefing reports) and identification of relevant target audiences. 
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